ZURA · Insider Trading
Zura Bio Limited Class A Ordinary Shares
Every open-market purchase and sale reported by ZURA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | Jennifer Jarrett | Director | A | +51,000 deriv. | — |
| 2026-06-22 | Parvinder Thiara | Director | A | +51,000 deriv. | — |
| 2026-06-22 | Daniel J. Becker | Director | A | +51,000 deriv. | — |
| 2026-06-22 | Ajay Nirula | Director | A | +51,000 deriv. | — |
| 2026-06-22 | Steven J Schoch | Director | A | +51,000 deriv. | — |
| 2026-06-22 | Mark Eisner | Director | A | +51,000 deriv. | — |
| 2026-06-22 | Amit Munshi | Director | A | +51,000 deriv. | — |
| 2026-04-02 | Sandeep Chidambar Kulkarni | Chief Executive Officer | A | +894,000 deriv. | — |
| 2026-04-02 | Gary Whale | Chief Technology Officer | A | +263,000 deriv. | — |
| 2026-04-02 | Eric J Hyllengren | Chief Financial Officer | A | +340,900 deriv. | — |
| 2026-04-02 | Kiran Nistala | See Remarks | A | +340,900 deriv. | — |
| 2026-04-02 | Kim Davis | Chief Legal Officer | A | +425,700 deriv. | — |
| 2026-03-05 | Ajay Nirula | Director | A | +37,812 deriv. | — |
| 2026-03-02 | AI Biotechnology LLC | 10%+ Owner | Buy | +8,000,000 | +$50.00M |
| 2026-02-24 | Mark Eisner | Director | A | +37,812 deriv. | — |
| 2026-01-27 | Parvinder Thiara | Director | A | +38,823 deriv. | — |
| 2026-01-23 | Sandeep Chidambar Kulkarni | Chief Executive Officer | A | +2,934,107 deriv. | — |
| 2025-07-17 | Eric J Hyllengren | Chief Financial Officer | A | +672,000 deriv. | — |
| 2025-05-29 | Daniel J. Becker | Director | A | +51,000 deriv. | — |
| 2025-05-22 | Jennifer Jarrett | Director | A | +51,000 deriv. | — |
| 2025-05-22 | Someit Sidhu | Director | A | +51,000 deriv. | — |
| 2025-05-22 | Neil Murray Hamilton Graham | Director | A | +51,000 deriv. | — |
| 2025-05-22 | Amit Munshi | Director | A | +51,000 deriv. | — |
| 2025-05-22 | Sandeep Chidambar Kulkarni | Director | A | +51,000 deriv. | — |
| 2025-05-22 | van Amstel Arnout Ploos | Director | A | +51,000 deriv. | — |
| 2025-05-22 | Steven J Schoch | Director | A | +51,000 deriv. | — |
| 2025-05-12 | Verender S. Badial | Chief Financial Officer | A | +303,100 deriv. | — |
| 2025-03-03 | Kim Davis | Chief Legal Officer | A | +488,800 deriv. | — |
| 2025-03-03 | Robert Lisicki | Chief Executive Officer | A | +1,153,000 deriv. | — |
| 2025-03-03 | Kiran Nistala | See Remarks | A | +341,700 deriv. | — |
| 2025-03-03 | Gary Whale | Chief Technology Officer | A | +302,000 deriv. | — |
| 2024-12-31 | Kim Davis | Chief Legal Officer | A | +1,500 | — |
| 2024-12-11 | van Amstel Arnout Ploos | Director | A | +117,000 deriv. | — |
| 2024-12-11 | Sandeep Chidambar Kulkarni | Director | A | +117,000 deriv. | — |
| 2024-12-11 | Parvinder Thiara | Director | A | +117,000 deriv. | — |
| 2024-12-11 | Neil Murray Hamilton Graham | Director | A | +117,000 deriv. | — |
| 2024-12-11 | Jennifer Jarrett | Director | A | +117,000 deriv. | — |
| 2024-12-11 | Robert Lisicki | Chief Executive Officer | A | +117,000 deriv. | — |
| 2024-12-11 | Amit Munshi | Director | A | +117,000 deriv. | — |
| 2024-12-11 | Steven J Schoch | Director | A | +117,000 deriv. | — |
| 2024-12-11 | Someit Sidhu | Director | A | +117,000 deriv. | — |
| 2024-11-27 | Parvinder Thiara | Director | Sell | −1,001,633 | −$2.73M |
| 2024-09-13 | Parvinder Thiara | Director | Sell | −3,800,000 | −$10.26M |
| 2024-09-09 | Kiran Nistala | See Remarks | A | +3,195 | +$10.00K |
| 2024-09-06 | Michael Howell | See Remarks | A | +7,987 | +$25.00K |
| 2024-09-06 | Someit Sidhu | Director | A | +1,186,901 | +$3.72M |
| 2024-09-06 | Someit Sidhu | Director | Sell | −51,728 | −$200.19K |
| 2024-09-06 | Amit Munshi | Director | A | +159,744 | +$500.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| AI Biotechnology LLC | 10%+ Owner | 6,552,725 | $26.80M |
| Someit Sidhu | Director | 3,272,319 | $13.38M |
| Amit Munshi | Director | 777,384 | $3.18M |
| Kim Davis | Chief Legal Officer | 492,881 | $2.02M |
| Kiran Nistala | See Remarks | 3,195 | $13.07K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZURA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.